Home / Business and Economy / Novo Nordisk Offers $499 Monthly Ozempic for Uninsured Diabetes Patients
Novo Nordisk Offers $499 Monthly Ozempic for Uninsured Diabetes Patients
18 Aug
Summary
- Novo Nordisk offers $499 monthly Ozempic for cash-paying diabetes patients
- Novo and GoodRx partner to sell Wegovy and Ozempic directly to consumers
- Novo expects Ozempic cash sales to account for 10% of total prescriptions
On August 18, 2025, Novo Nordisk announced it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. The company is making the medication available through its own pharmacy, a tie-up with telehealth service GoodRx, and other platforms.
This move by Novo Nordisk comes as the Danish drugmaker and its rival Eli Lilly have been expanding into direct-to-consumer sales for their highly effective and in-demand diabetes and weight-loss medicines. This is partly due to competition from online telehealth companies and pharmacies that sell cheaper compounded versions of these drugs.
Novo Nordisk already sells the weight-loss version of Ozempic, called Wegovy, through its NovoCare pharmacy for $499 per month. The company expects Ozempic cash sales to account for about 10% of total prescriptions, the same level of market penetration it has experienced with Wegovy.
